# Biotech Daily Digest ‚Äî 2025-10-04

**4 items from 2 sources**

## Summary by Source

- Endpoints News: 3 items
- Fierce Biotech: 1 item


## Endpoints News

- **[Pfizer‚Äôs ‚Äòmost favored nation‚Äô deal; Metsera‚Äôs obesity data; Takeda stops cell therapy work; and more](https://endpoints.news/pfizers-most-favored-nation-deal-metseras-obesity-data-takeda-stops-cell-therapy-work-and-more/)**  
  _Sat, 04 Oct 2025 10:00:39 +0000_  
  Good morning, and welcome back to Endpoints Weekly! We‚Äôve got a lot of news to recap this week, so pull up a seat and let‚Äôs get to it.

 Pharma reporter Max Bayer was in the ...

- **[BridgeBio‚Äôs GondolaBio bet skirts industry‚Äôs focus on small pipelines](https://endpoints.news/bridgebios-gondolabio-bet-skirts-industrys-focus-on-small-pipelines/)**  
  _Fri, 03 Oct 2025 18:37:53 +0000_  
  BridgeBio has been quietly building a sprawling pipeline at its private spinout GondolaBio.

 The rare disease startup launched last year with a few of BridgeBio‚Äôs rare disease assets and $300 million in ...

- **[FDA OKs Zepzelca-Tecentriq combo; CSL Vifor‚Äôs layoffs](https://endpoints.news/fda-oks-zepzelca-tecentriq-combo-csl-vifors-layoffs/)**  
  _Fri, 03 Oct 2025 15:07:31 +0000_  
  Plus, news about Egetis Therapeutics, Palisade Bio and Enanta Pharmaceuticals:

 ü´Å FDA approves Zepzelca-Tecentriq combo in lung cancer: Jazz and Roche each said the combination of their drugs is now cleared ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/4-reasons-why-life-sciences-still-fails-women-top-despite-female-majority-workforce-report" hreflang="en">4 reasons why life sciences still fail women at the top, despite a female-majority workforce: report</a>](https://www.fiercebiotech.com/biotech/4-reasons-why-life-sciences-still-fails-women-top-despite-female-majority-workforce-report)**  
  _Oct 3, 2025 10:56am_  
  Biopharma is set to lose two of the industry‚Äôs rare women CEOs‚ÄîGSK‚Äôs Emma Walmsley and Merck KGaA's Bel√©n Garijo‚Äîleaving a dearth of women-helmed large life sciences companies.
